SEER - sporedata/researchdesigneR GitHub Wiki

General description

The Surveillance, Epidemiology, and End Results (SEER) Program is run by the National Cancer Institute (NCI) and is a key source for cancer statistics (cancer incidence and survival) in the United States. Currently, SEER represents about 48% of the U.S. population (42% of Whites, 44.7% of African Americans, 66.3% of Hispanics, 59.9% of American Indians and Alaska Natives, 70.7% of Asians, and 70.3% of Hawaiian/Pacific Islanders), gathering data on cancer incidence, survival, and patient demographics from various cancer registries.

Since it collected its first data on cancer cases on January 1, 1973, SEER continuously expands its scope, contributing significantly to cancer surveillance and research efforts in the U.S, in an effort to reduce the burden of cancer among the U.S. population. The data collected includes information on patient demographics, first course of treatment, patient survival, and tumor characteristics (primary tumor site, tumor morphology and stage at diagnosis), and follow-up for vital status making it the only comprehensive resource in the U.S. that incorporates cancer stage at diagnosis and patient survival data.

SEER's mortality data is sourced from the National Center for Health Statistics, and its population data for calculating cancer rates comes from the Census Bureau. Its data is updated annually and is available in as a public service in print and electronic formats to support researchers, health professionals, and policymakers.

Variable categories

• SEER has information on patient demographics, primary tumor site, tumor morphology and stage at diagnosis, first course of treatment, and follow-up for vital status for persons with cancer.

Related publications

• Socioeconomic Factors Associated With Thymoma Survival in the United States
• Predicting cutaneous malignant melanoma patients' survival using deep learning: a retrospective cohort study
• Neighborhood socioeconomic status and race are associated with incidence disparities in oral cavity cancers
• Twenty-year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors
• Prognostic Significance of Pathologic Lymph Node Invasion in Metastatic Renal Cell Carcinoma in the Immunotherapy Era
• Personalized prognostic prediction tool for high-grade neuroendocrine cervical cancer: a SEER database analysis and single-center validation
• Does primary tumor resection improve survival for patients with sarcomas of pelvic bones, sacrum, and coccyx who have metastasis at diagnosis?
• Prognostic Value of Tumor Deposits in Stage III Colorectal Cancer Patients with Different N Stages: A Population-Based, Retrospective, Cohort Study
• A predictive model for patients with local-regionally advanced oropharyngeal squamous cell carcinoma treated after cervical lymph node dissection
• Enhancing prognostic accuracy: a SEER-based analysis for overall and cancer-specific survival prediction in cervical adenocarcinoma patients
• Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA
• A Population-Based Research Utilized a Risk Stratification Model to Forecast the Overall Survival of Young Women With Diagnosed Stage IV Breast Cancer
• Guiding the postoperative radioactive iodine-131 therapy for patients with papillary thyroid carcinoma according to the prognostic risk groups: a SEER-based study
• Secondary Breast Angiosarcoma After a Primary Diagnosis of Breast Cancer: A Retrospective Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database
• Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019

Data access

More information about SEER can be found at https://seer.cancer.gov/

To access SEER data, visit https://seer.cancer.gov/data-software/